Inferra AI / Company / CYTK
Cytokinetics Inc.
CYTK · Health Care
Last earnings Aug 6, 2026
Key results
Total revenuequarter
$66.8 million
Revenues • Total revenues for the second quarter of 2025 were $66.8 million compared to $0.2 million for the same period in 2024.
SEC original ↗Cytokinetics Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
$52.4 million
Revenues in the second quarter of 2025 included the recognition of $52.4 million related to the Company’s license and collaboration agreement for aficamten in Japan with Bayer, and $11.7 million for the achievement of clinical milestones in the non-obstructive HCM and obstructive HCM trials in Japan.
SEC original ↗Cytokinetics Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Research and developmentquarter
$112,554 thousand
Research and development 112,554 79,597 212,395 161,167
SEC original ↗Cytokinetics Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $66.8 million | — | $0.2 million |
| Revenue | $52.4 million | — | — |
| Research and development | $112,554 thousand | — | — |
Guidance · company-stated
Direction: Reiterated
“2025 Financial Guidance The company is maintaining its full year 2025 financial guidance: GAAP operating expense* $670 million to $710 million Non-cash stock-based compensation expense included in GAAP operating expense $120 million to $110 million *GAAP operating expense comprised of R&D and SG&A expenses.”
Classified from the release's primary full-year outlook statement.
Capital allocation
The Company received $75 million in proceeds from the drawing on Tranche 4 of the Royalty Pharma Multi Tranche Term Loan in the second quarter of 2025.
Bank National Association) 2026 Notes Cytokinetics 4% convertible senior notes due 2026 2027 Indenture Indenture, dated July 6, 2022, between Cytokinetics and U.
Event summary
CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Company outlook: “2025 Financial Guidance The company is maintaining its full year 2025 financial guidance: GAAP operating expense* $670 million to $710 million Non-cash stock-based compensation expense included in GAAP operating expense $120 million to $110 million *GAAP operating expense comprised of R&D and SG&A expenses.”
Company outlook — Reiterated (“maintaining”)
“2025 Financial Guidance The company is maintaining its full year 2025 financial guidance: GAAP operating expense* $670 million to $710 million Non-cash stock-based compensation expense included in GAAP operating expense $120 million to $110 million *GAAP operating expense comprised of R&D and SG&A expenses.”
Classified from the release's primary full-year outlook statement.
Capital allocation
The Company received $75 million in proceeds from the drawing on Tranche 4 of the Royalty Pharma Multi Tranche Term Loan in the second quarter of 2025.
SEC original ↗Cytokinetics Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Bank National Association) 2026 Notes Cytokinetics 4% convertible senior notes due 2026 2027 Indenture Indenture, dated July 6, 2022, between Cytokinetics and U.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Bank Trust Company, as trustee 2027 Notes Cytokinetics 3.50% convertible senior notes due 2027 2031 Indenture Indenture, dated September 19, 2025, between Cytokinetics and U.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
To date, we have funded operations primarily through sales of our common stock, contract payments under our collaboration agreements, sales of future revenues and royalties, debt financing arrangements, and interest income, but we will increasingly rely on revenues generated from the commercial sales of MYQORZO to fund our operations and cash expenditures.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Until we achieve profitable operations, we intend to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, and debt financings in addition to our commercial sales revenue.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Pursuant to the 2022 RPI Transactions, the RP Multi Tranche Loan Agreement and the RP Aficamten RPA described below, are determined to be debt instruments subsequently measured at amortized cost and were entered into with parties that were at the time of our entry into the 2022 RPI Transactions affiliated and in contemplation of one another.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
With our current balance sheet and additional access to capital, we are well-positioned to execute on both the commercialization and potential label expansion opportunities of aficamten while also advancing our later-stage specialty cardiovascular pipeline.
SEC original ↗Cytokinetics Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Until we achieve profitable operations, we intend to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, and debt financings in addition to our commercial sales revenue.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Our success is dependent on our ability to obtain additional capital by entering into financings or new strategic collaborations, and ultimately on our and our collaborators ability to successfully develop and market our drugs and drug candidates.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Alternatively, we might raise funds through strategic collaborations, public or private financings or other arrangements.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Legal Proceedings 39 Item 1A.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
SEC original ↗Cytokinetics Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q2 2026
- 8-KCYTK
Aug 28, 2026
- 8-KCYTK
Aug 13, 2026
- 10-QCYTK
Aug 6, 2026
- 8-KCYTK
Aug 6, 2026
- Q1 2026
- 8-KCYTK
May 27, 2026
- 8-KCYTK
May 8, 2026
- 8-KCYTK
May 5, 2026
- 10-QCYTK
May 5, 2026
- 8-KCYTK
May 5, 2026
- Q4 2025
- 10-KCYTK
Feb 26, 2026
- 8-KCYTK
Feb 24, 2026
- 8-KCYTK
Feb 17, 2026
- Q3 2025
- 8-KCYTK
Dec 19, 2025
- 8-KCYTK
Dec 12, 2025
- 8-KCYTK
Nov 14, 2025
- 10-QCYTK
Nov 5, 2025
- 8-KCYTK
Nov 5, 2025
- Q2 2025
- 8-KCYTK
Sep 22, 2025
- 8-KCYTK
Sep 16, 2025
- 8-K/ACYTK
Sep 8, 2025
- 8-KCYTK
Sep 3, 2025
- 8-KCYTK
Sep 2, 2025
- 8-KCYTK
Aug 20, 2025
- 10-QCYTK
Aug 7, 2025
- 8-KCYTK
Aug 7, 2025
- Q1 2025
- 8-KCYTK
May 16, 2025
- 10-QCYTK
May 6, 2025
- 8-KCYTK
May 6, 2025
- 8-KCYTK
May 1, 2025
- Q4 2024
- 8-KCYTK
Mar 10, 2025
- Q3 2006
- 8-KCYTK
Nov 27, 2006
- Q3 2005
- 10-QCYTK
Nov 10, 2005
Earnings releases
8 documentsPresentations
0 documentsNo presentations for Cytokinetics Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Cytokinetics Inc. are held in this edition of the library.
Mentioned by
6 companiesOther tracked companies whose held documents mention Cytokinetics Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“tements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking… … Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable ”
“tements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking… …stock-based compensation expense. The decrease was primarily due to higher cli”
“tements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking…”
“Company generates… …material, or the potential loss cannot be reasonably estimated. In re Cytokinetics, Incorporated Securities Litigation On September 17, 2025, a putative stockholder class action lawsuit was filed against the Company and… …covenant”
“tatements that express the companys opinions, expectations, beliefs,… …partnerships with Cytokinetics, PTC Therapeutics and Agios. In addition, reflecting our attractive fundamental outlook, we continued to repurchase our Class A ordinary shares as ”
“ solid tumours BioMap protein-level artificial intelligence platform multiple Corxel/Cytokinetics Myqorzo, cardiac myosine inhibitor obstructive and non-obstructive… …additional details, please refer to the slide 33. 3. Based on Sanofi Vara co”
See also the earnings calendar for every tracked company’s next earnings date.